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Obtaining large numbers of functional pancreatic islets via direct cellular reprogramming is an important
clinically relevant goal. In a recent issue of Cell Stem Cell, Li et al. (2014) report a new step-wise protocol
for generating islet cells from mouse embryonic fibroblasts using a combination of soluble molecules.For many years, transplantation of pan-
creatic islets to replace those lost to auto-
immune destruction has been considered
as a potential ‘‘cure’’ therapy for type 1
diabetes (Shapiro et al., 2000). Despite
the promise, clinical application of islet
transplantation has been limited due to
a severe shortage of transplant-quality
donor islets. This clinical bottleneck
has been pushing the field to develop
protocols for generating functional islet
cells in vitro from pluripotent human
embryonic and induced pluripotent
stem cells (hESCs and iPSCs), and
several such protocols has been derived
(D’Amour et al., 2006; Alipio et al., 2010).
Also, recent work identified a possible
alternative to differentiation from pluri-
potent cells, namely direct reprogram-
ming of somatic cells into cell types of
choice that bypass pluripotent state;
examples include conversion of fibro-
blasts into cardiomyocytes, neurons and
endothelial cells (Ieda et al., 2010; Vierbu-
chen et al., 2010; Li et al., 2013). Prior to
this work, however, fibroblasts have not
been directly reprogrammed into islet
cells. Now Li et al. (2014) demonstrate
that a unique combination of soluble
molecules can convert mouse embryo-
nic fibroblasts (MEFs) into proliferation-
competent definitive endoderm-like
cells (DELCs), pancreatic progenitor-like
cells (PPLCs), and insulin-producing b-
and other pancreatic-like cells (PLCs)
(Figure 1).
As a cell source, the authors used
engineered MEFs where four classical
Yamanaka factors, Oct4, Sox2, Klf4, and
c-Myc, are induced by addition of doxy-
cycline (DOX). This step initiates erasure
of the MEFs’ epigenetic memory to drive
them toward pluripotency (Figure 1).Li et al. (2014) hypothesized that exposing
MEFs to lineage-specific signals (Activin
A and LiCl) during early stages of epige-
netic remodeling would initiate lineage-
specific reprogramming into definitive
endoderm. Using coexpression of Sox17
and Foxa2—two relatively specific defini-
tive endoderm markers—as the readout,
they were indeed able to generate endo-
derm-like cells, DELCs. Interestingly,
addition of Activin A (AA) and LiCl at
the time of initial DOX-mediated gene in-
duction was found to be significantly
more effective for DELC generation than
delayed addition. With these optimized
conditions, about 54% of all cells in
the culture coexpressed Sox17, Foxa2,
and other definitive endoderm markers,
and only few nonendodermal cell were
present. Importantly, it was possible
to isolate DELCs and expand them in
serial passages for over a month with-
out losing differentiation potential trans-
lating into about 65,000-fold increase
in DELC numbers. Also noteworthy was
that activation of pluripotency genes did
not result in generation of fully repro-
grammed iPSCs suggesting that early
initiation of lineage-specific signals can
prevent MEFs from progressing to pluri-
potency. To test whether the DELCs
possess the capacity to give rise to
pancreatic-like PPLCs, the authors
took advantage of published pluripotent
cell pancreatic differentiation protocols
(D’Amour et al., 2006; Li et al., 2011),
and found that about 1% of differentiated
cells coexpressed pancreatic progenitor
cell markers, pancreatic and duodenal
homeobox gene-1 (PDX-1) and NK
homeobox factor 6.1 (Nkx6.1). Further
differentiation of PPLCs generated about
0.1% insulin and C-peptide producingCell Metabolismcells that did not properly release insulin
in response to glucose.
While useful as a proof of principle,
these results revealed the need for pro-
tocol optimization. To this end the
authors screened DELCs on the library
of 400 small-molecule compounds using
coexpression of Pdx-1 and Nkx6.1 as
the readout. The screen had identified
several useful hits—specifically, retinoic
acid (RA), transforming growth factor-b
receptor inhibitor (A83-01), 2-phospho-
L-ascorbic acid (pVc), and a Hedgehog
pathway inhibitor (LDE225). With this
combination, the yield of Pdx-1+/
Nkx6.1+ PPLCs was increased from the
original 1% to 8%. In an attempt to further
improve PPLC yields, the authors tested
whether it might be beneficial to expose
the cultures to small molecules during
the initial Dox-mediated gene activa-
tion (DELC commitment). Accordingly,
histone lysine methyltransferase G9a
inhibitor (Bix-01294) and pVc, further in-
creased the number of Pdx-1+/Nkx6.1+
to 30%, thus demonstrating that influ-
encing early steps of lineage commitment
can impact later differentiation steps.
Interestingly, no further increase in Pdx-
1+/Nkx6.1+ DELCs was detected under
these conditions.
A final chemical screen resulted in an
improvement of PLCs yield: a combina-
tion of p38 inhibitor (SB203580) and pVc
had increased the number of insulin+/
PDX-1+ cells to about 2% from the initial
0.1%. In addition to b-like insulin-produc-
ing cells, other islet cell types as well
as exocrine acinar-like cells were gene-
rated. Most PLCs expressed single
hormones implying some level of func-
tional maturity. However, compared
to native mouse islets, the PLCs had19, April 1, 2014 ª2014 Elsevier Inc. 551
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Figure 1. Small Molecules Reprogram Mouse Embryonic
Fibroblasts into Pancreatic Islet-like Cells Bypassing Pluripotent
State
Following induction of pluripotency genes, the unique combinations of small
molecules guide direct reprogramming of embryonic fibroblasts into definitive
endoderm-like cells, pancreatic progenitor-like cells, and pancreatic-like
cells. This protocol is faster, more efficient, and potentially safer than
earlier-developed protocols involving full reprogramming of fibroblasts into
iPSCs followed by their differentiation into pancreatic-like cells.
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Previewsimpaired insulin release in
response to glucose. Lastly,
under kidney capsule trans-
plantation of PPLCs into
chemically induced diabetic
mouse model resulted in a
functional maturation of the
cells and ameliorated diabetic
hyperglycemia. Importantly,
following nephrectomy, the
mice returned to diabetic
state indicating a direct
contribution of the b-like cells
to the observed therapeutic
effect.
In conclusion, this study
demonstrates for the first
time that nonendoderm cells
such as fibroblasts can be
converted across germ-layer
boundary into endoderm
islet-like cells. Moreover, this
work defines a novel strategy
where such a conversion can
be accomplished by a combi-nation of small molecules. An important
open question remains, however: Is
this strategy applicable to human post-
natal somatic cells? While direct reprog-
ramming is faster, more efficient, and
potentially safer than differentiation from
pluripotent cells (Figure 1), direct reprog-
ramming protocols generally do not pro-
duce large numbers of differentiated cells.
In this regard demonstration of a substan-
tial expansion capacity of the DELCs is
significant, as it suggests that a large-
scale production of islet-like cells could
be achieved via direct reprogramming.
The in vitro generation of islet-like cells552 Cell Metabolism 19, April 1, 2014 ª2014from hESCs and iPSCs can now be
accomplished on a routine basis, but
these cells are usually functionally imma-
ture as they do not properly respond to
glucose (Nostro and Keller, 2012). Their
maturation can be induced in vivo, and
the same response has been observed
in this work for directly reprogrammed
cells, suggesting a common develop-
mental block that might be possible
to address by similar strategies. Lastly,
the need to activate pluripotency genes
to jumpstart direct reprogramming is
a drawback. Current work to over-
come this requirement gives reasonsElsevier Inc.for optimism, and opens
potential opportunities for
developing small molecule-
mediated in vivo direct repro-
gramming protocols without
gene transfer.
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